Efficacy of keverprazan for duodenal ulcer: A phase II randomized, double‐blind, parallel‐controlled trial
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Gastroenterology and Hepatology"
DOI: 10.1111/jgh.16000
Abstract: Considering the limitation of varying acid suppression of proton pump inhibitors, this study was aimed to assess the efficacy, safety, and dose–effect relationship of keverprazan, a novel potassium‐competitive acid blocker, in the treatment of duodenal… read more here.
Keywords: duodenal ulcer; efficacy keverprazan; efficacy; phase randomized ... See more keywords